Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas

Gwendolyn van Gorkom; Herve Finel; Sebastian Giebel; David Pohlreich; Avichai Shimoni; Mark Ringhoffer; Gulsan Sucak; Nicolaas Schaap; Peter Dreger; Anna Sureda; Harry C. Schouten

doi:10.1002/jca.21506

Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas

Gwendolyn van Gorkom^*
, Herve Finel
, Sebastian Giebel
, David Pohlreich
, Avichai Shimoni
, Mark Ringhoffer
, Gulsan Sucak
, Nicolaas Schaap
, Peter Dreger
, Anna Sureda
, Harry C. Schouten

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96%), but there was a large variation in chemotherapy schedules. Thirty (11%) of them were poor mobilizers (

Original language	English
Pages (from-to)	295-301
Number of pages	7
Journal	Journal of Clinical Apheresis
Volume	32
Issue number	5
DOIs	https://doi.org/10.1002/jca.21506
Publication status	Published - Oct 2017

Keywords

relapsed lymphomas
stem cell mobilization
BONE-MARROW-TRANSPLANTATION
NON-HODGKINS-LYMPHOMA
POOR MOBILIZATION
RISK-FACTORS
CHEMOTHERAPY
FILGRASTIM
TRIAL

Access to Document

10.1002/jca.21506

Cite this

@article{94f8c724d2924649a99c701800e4bd44,

title = "Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas",

abstract = "High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96\%), but there was a large variation in chemotherapy schedules. Thirty (11\%) of them were poor mobilizers (",

keywords = "relapsed lymphomas, stem cell mobilization, BONE-MARROW-TRANSPLANTATION, NON-HODGKINS-LYMPHOMA, POOR MOBILIZATION, RISK-FACTORS, CHEMOTHERAPY, FILGRASTIM, TRIAL",

author = "\{van Gorkom\}, Gwendolyn and Herve Finel and Sebastian Giebel and David Pohlreich and Avichai Shimoni and Mark Ringhoffer and Gulsan Sucak and Nicolaas Schaap and Peter Dreger and Anna Sureda and Schouten, \{Harry C.\}",

year = "2017",

month = oct,

doi = "10.1002/jca.21506",

language = "English",

volume = "32",

pages = "295--301",

journal = "Journal of Clinical Apheresis",

issn = "0733-2459",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas

AU - van Gorkom, Gwendolyn

AU - Finel, Herve

AU - Giebel, Sebastian

AU - Pohlreich, David

AU - Shimoni, Avichai

AU - Ringhoffer, Mark

AU - Sucak, Gulsan

AU - Schaap, Nicolaas

AU - Dreger, Peter

AU - Sureda, Anna

AU - Schouten, Harry C.

PY - 2017/10

Y1 - 2017/10

N2 - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96%), but there was a large variation in chemotherapy schedules. Thirty (11%) of them were poor mobilizers (

AB - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96%), but there was a large variation in chemotherapy schedules. Thirty (11%) of them were poor mobilizers (

KW - relapsed lymphomas

KW - stem cell mobilization

KW - BONE-MARROW-TRANSPLANTATION

KW - NON-HODGKINS-LYMPHOMA

KW - POOR MOBILIZATION

KW - RISK-FACTORS

KW - CHEMOTHERAPY

KW - FILGRASTIM

KW - TRIAL

U2 - 10.1002/jca.21506

DO - 10.1002/jca.21506

M3 - Article

SN - 0733-2459

VL - 32

SP - 295

EP - 301

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

IS - 5

ER -

Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas

Abstract

Keywords

Access to Document

Fingerprint

Cite this